Table 2.

Effect of KCNJ2/Kir2.1 on drug sensitivity $\left(\overline{\mathsf{X}}\mathbf{\pm }\mathsf{s}\mathbf{,}\mathbf{n}\mathbf{=}\mathsf{3}\mathbf{,}\mathsf{\mu g}/\mathsf{ml}\right)$

Cells	IC50
	ADM	CDDP	VP-16
H69	5.222 ± 0.117	17.711 ± 0.279	124.03 ± 2.791
H69-NC	5.426 ± 0.87	17.548 ± 0.423	122.27 ± 2.938
H69-KCNJ2	13.678 ± 0.195*	22.649 ± 7.623*	283.41 ± 6.884*
H446	4.293 ± 0.049	4.529 ± 0.063	52.342 ± 3.0
H446-NC	4.412 ± 0.212	4.884 ± 0.068	50.296 ± 1.53
H446-KCNJ2	14.048 ± 0.242*	15.303 ± 0.712*	80.064 ± 4.97*
H69AR	211.06 ± 6.665	76.652 ± 1.238	531.58 ± 6.06
H69AR-shNC	209.69 ± 3.157	77.32 ± 1.362	529.72 ± 4.704
H69AR-shKCNJ2-1	62.275 ± 1.214*	44.583 ± 1.514*	394.74 ± 19.996*
H69AR-shKCNJ2-2	18.823 ± 0.935*	33.183 ± 2.637*	359.51 ± 8.62*
H446AR	39.29 ± 0.738	133.73 ± 4.875	179.63 ± 2.978
H446AR-shNC	42.35 ± 1.388	132.12 ± 4.434	175.64 ± 8.726
H446AR-shKCNJ2-1	27.082 ± 2.289*	72.724 ± 0.896*	118.31 ± 4.934*
H446AR-shKCNJ2-2	19.920 ± 0.688*	21.517 ± 2.693*	108.51 ± 5.772*

*P < 0.05 (compared with corresponding negative control groups).